Tailoring Cancer Treatment: Key Insights from the 2026 World Cancer Congress

In the evolving landscape of cancer care, the need for localized treatment strategies has become increasingly evident. The 2026 World Cancer Congress, held in Hong Kong, served as a significant platform for discussing how best to adapt cancer treatment guidelines to suit regional needs. Organized by the Union for International Cancer Control, this biannual event brought together a diverse group of attendees, including clinicians, researchers, policymakers, and advocates from over 120 countries. A focal point of the Congress was the work of the National Comprehensive Cancer Network (NCCN), an alliance of premier cancer centers in the United States, dedicated to shaping effective cancer care policies globally.

NCCN’s Commitment to Global Cancer Care

At the Congress, NCCN presented original research abstracts emphasizing the importance of regionally tailored clinical practice guidelines as part of National Cancer Control Plans (NCCPs). These government-led initiatives are vital for establishing national standards for cancer prevention, screening, and treatment.

Matt Izzo, an NCCN Senior Specialist, highlighted that while the majority of active NCCPs include references to established treatment guidelines, many still lack methods for effectively measuring their implementation. This lack of monitoring is concerning, as it undermines equity and quality in cancer care. The research revealed significant opportunities for improvement, particularly with respect to enhancing guidelines around disease staging—an essential aspect for crafting interventions that address local cancer trends.

Highlighting China’s Adaptations

A significant part of the presentations included insights from NCCN’s collaborative work to adapt guidelines for nasopharyngeal carcinoma in China. Doctors Jun Ma and Ying Sun from Sun Yat-sen University Cancer Center partnered with NCCN to develop specific adaptations of the NCCN Clinical Practice Guidelines for oncology, creating tailored recommendations to fit China's unique clinical environment.

The adaptations not only considered the availability of medications that are unique to China but also took into account the extensive local clinical experience that differs from practices in Western countries. Dr. Ma stated, "These guidelines are designed based on local clinical data, which enhances their relevance and effectiveness in addressing the healthcare challenges we face due to the higher prevalence of nasopharyngeal cancer in our region."

Engaging Global Decision-Makers

Crystal S. Denlinger, CEO of NCCN, expressed the organization's goal to ensure that everyone has access to high-quality cancer prevention and treatment—regardless of their location. The platform provided by the World Cancer Congress allows NCCN to engage directly with decision-makers worldwide about important cancer care policies and practices.

With nearly half of all registered NCCN guidelines users located internationally, there is a strong desire for knowledge sharing and collaboration across borders. As NCCN continues to adapt its guidelines for various regions, it ensures that crucial research insights and clinical recommendations reach healthcare professionals who require them the most.

Looking Toward the Future

The World Cancer Congress is a vital opportunity not only for sharing research findings but also for fostering partnerships aimed at improving cancer care across the globe. NCCN’s commitment to making evidence-based guidelines accessible will continue to play a pivotal role in shaping cancer treatment policies.

For more information on the developments from the World Cancer Congress and resources available for patients and caregivers, visit NCCN's website. Together, we can advance the standard of cancer care worldwide, ensuring that no one area is left behind in the fight against this formidable disease.